List of works - Emily J Hanan

2-Aminobenzimidazoles as potent Aurora kinase inhibitors.

scientific article

4-Aminoindazolyl-dihydrofuro[3,4-d]pyrimidines as non-covalent inhibitors of mutant epidermal growth factor receptor tyrosine kinase

scientific article

Correction to Noncovalent Mutant Selective Epidermal Growth Factor Receptor Inhibitors: A Lead Optimization Case Study

scientific article published on 11 March 2016

Design and synthesis of 2-amino-isoxazolopyridines as Polo-like kinase inhibitors

scientific article

Design and synthesis of 2-amino-pyrazolopyridines as Polo-like kinase 1 inhibitors

scientific article

Discovery and Development of Potent LFA-1/ICAM-1 Antagonist SAR 1118 as an Ophthalmic Solution for Treating Dry Eye.

scientific article

Discovery and optimization of C-2 methyl imidazopyrrolopyridines as potent and orally bioavailable JAK1 inhibitors with selectivity over JAK2

scientific article

Discovery of a Noncovalent, Mutant-Selective Epidermal Growth Factor Receptor Inhibitor

scientific article

Discovery of a class of highly potent Janus Kinase 1/2 (JAK1/2) inhibitors demonstrating effective cell-based blockade of IL-13 signaling

scientific article published on 04 April 2019

Discovery of a potent and selective aurora kinase inhibitor

scientific article

Discovery of potent and selective pyrazolopyrimidine janus kinase 2 inhibitors

scientific article

Discovery of selective and noncovalent diaminopyrimidine-based inhibitors of epidermal growth factor receptor containing the T790M resistance mutation

scientific article

Discovery of tetrahydroisoquinoline (THIQ) derivatives as potent and orally bioavailable LFA-1/ICAM-1 antagonists

scientific article published on 23 July 2010

Monomeric targeted protein degraders

scientific article published on 30 April 2020

Noncovalent Mutant Selective Epidermal Growth Factor Receptor Inhibitors: A Lead Optimization Case Study

scientific article

Optimization of globomycin analogs as novel gram-negative antibiotics

scientific article published on 05 August 2020

Pyridones as Highly Selective, Noncovalent Inhibitors of T790M Double Mutants of EGFR.

scientific article published on 17 December 2015

Structure of the essential inner membrane lipopolysaccharide-PbgA complex

scientific article published on 12 August 2020

Structure of theBrachydanio rerioPolo-like kinase 1 (Plk1) catalytic domain in complex with an extended inhibitor targeting the adaptive pocket of the enzyme

scientific article

Structure–activity relationship (SAR) of the α-amino acid residue of potent tetrahydroisoquinoline (THIQ)-derived LFA-1/ICAM-1 antagonists ⬇️

scientific article published on 05 November 2010

Unstable Mechanisms of Resistance to Inhibitors of Escherichia coli Lipoprotein Signal Peptidase

scientific article published on 08 September 2020

List of works by Emily J Hanan

2-Aminobenzimidazoles as potent Aurora kinase inhibitors.

4-Aminoindazolyl-dihydrofuro[3,4-d]pyrimidines as non-covalent inhibitors of mutant epidermal growth factor receptor tyrosine kinase

Correction to Noncovalent Mutant Selective Epidermal Growth Factor Receptor Inhibitors: A Lead Optimization Case Study

Design and synthesis of 2-amino-isoxazolopyridines as Polo-like kinase inhibitors

Design and synthesis of 2-amino-pyrazolopyridines as Polo-like kinase 1 inhibitors

Discovery and Development of Potent LFA-1/ICAM-1 Antagonist SAR 1118 as an Ophthalmic Solution for Treating Dry Eye.

Discovery and optimization of C-2 methyl imidazopyrrolopyridines as potent and orally bioavailable JAK1 inhibitors with selectivity over JAK2

Discovery of a Noncovalent, Mutant-Selective Epidermal Growth Factor Receptor Inhibitor

Discovery of a class of highly potent Janus Kinase 1/2 (JAK1/2) inhibitors demonstrating effective cell-based blockade of IL-13 signaling

Discovery of a potent and selective aurora kinase inhibitor

Discovery of potent and selective pyrazolopyrimidine janus kinase 2 inhibitors

Discovery of selective and noncovalent diaminopyrimidine-based inhibitors of epidermal growth factor receptor containing the T790M resistance mutation

Discovery of tetrahydroisoquinoline (THIQ) derivatives as potent and orally bioavailable LFA-1/ICAM-1 antagonists

Monomeric targeted protein degraders

Noncovalent Mutant Selective Epidermal Growth Factor Receptor Inhibitors: A Lead Optimization Case Study

Optimization of globomycin analogs as novel gram-negative antibiotics

Pyridones as Highly Selective, Noncovalent Inhibitors of T790M Double Mutants of EGFR.

Structure of the essential inner membrane lipopolysaccharide-PbgA complex

Structure of theBrachydanio rerioPolo-like kinase 1 (Plk1) catalytic domain in complex with an extended inhibitor targeting the adaptive pocket of the enzyme

Structure–activity relationship (SAR) of the α-amino acid residue of potent tetrahydroisoquinoline (THIQ)-derived LFA-1/ICAM-1 antagonists ⬇️

Unstable Mechanisms of Resistance to Inhibitors of Escherichia coli Lipoprotein Signal Peptidase